Peripheral Stent Implants Market Segmented By Bare Metal Stents (BMS), Covered Stents, Drug Eluting Stents (DES) Product with Carotid Artery Stents, Fem-Pop Artery Stents, Iliac Artery Stents, Infrapop Artery Stents Artery Type
Industry: Healthcare
Published Date: February-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP32225
The global revenue from the Peripheral Stent Implants Market was approximately US$ 3.6 Billion in 2022, with the global market expected to grow at a CAGR of 6.7% to reach a valuation of approximately US$ 7.2 Billion by the end of 2033.
|
Market Size (2023) |
US$ 3.8 Billion |
|
Projected Market Value (2033) |
US$ 7.2 Billion |
|
Global Market Growth Rate (2015 to 2022) |
6.7% CAGR |
|
Market Share of Top 5 Countries (2022) |
62.8% |
As assessed by Persistence Market Research, bare metal stents (BMS) held a market share of around 75.9% in the global market, in 2022. Overall, peripheral stent implants market sales account for around 75.6% of revenue share in the global peripheral vascular devices market, which was valued at around US$ 4.7 Billion in 2022.
The global peripheral stent implants market recorded a historic CAGR of 5.6% in the last 7 years from 2015 to 2022.
A peripheral stent can be used to treat narrowed arteries caused by peripheral artery disease (PAD), a condition in which plaque accumulates in the arteries that carry blood to the limbs, kidney, gut, and brain, as well as the abdomen. Peripheral, intravascular, or endovascular stents are synthetic tubular mesh structures are used to improve vessel potency in graft or native vasculature. A stent is designed to provide mechanical radial support after placement. After the stent is placed in the desired location, it is expanded using a balloon or self-expanding mechanism.
Recent and ongoing advancements in radiotherapy, gene therapy, imaging material and device technologies, and implementation have expanded the treatment options for PAD. Techniques for percutaneous interventions include balloon angioplasty, excisional atherectomy, and drug-eluting technologies. Such minimally invasive techniques have become an integral part of treatment by reducing morbidity and mortality while also improving quality of life.
Low treatment risk in endovascular intervention procedures creates an advantageous situation for patients, suppliers, and key players, resulting in significant opportunities for the peripheral stent implants market. Peripheral stents can be a great option for acute recoil and stenosis incidences because they are less invasive techniques, cost-effective, and have a faster recovery time than surgical revascularization.
Manufacturers of peripheral stents have significant opportunities by focusing on development of innovative reabsorbable stents as well as peripheral local drug delivery like antiproliferative and antithrombotic drugs for the treatment and prevention of restenosis with reduced side effects or complications such thrombosis and bleeding.
Technological advances in angioplasty surgeries have given cardiologists more options such as stenting, catheterization, and so on. As a result, rapid advances in medical technology are expected to drive demand for peripheral stent implants over the forecast period. The device is intended to support artery walls and reduce the chances of strokes. For example, the Japanese Ministry of Health approved the market for BIOTRONIK's Orsiro1 coronary drug-eluting stent (Orsiro DES) in January 2018.
“Rising Patient Base, Growing Geriatric Population, and Favorable Reimbursement Policies”
From last few years, PAD has increased with rise in PAD-attributable disease burden. According to a 2022 article published in the journal 'Life' on the epidemiology of peripheral artery disease, coronary and cerebrovascular risk factors of PAD such as smoking, diabetes mellitus, and hypercholesterolemia are associated with cardiovascular diseases (CVD) morbidity and mortality.
According to published article on PAD in Circulation Research in 2021, atherosclerotic lower extremity peripheral artery disease (PAD) is affecting more than 230 million globally and has become a cause of cardiovascular morbidity and mortality.
The growing demand for stents during surgeries among the geriatric population with PAD, combined with longer life expectancies, has created enormous opportunities for manufacturers. The number of endovascular interventions is rising with growing awareness of cost-effective treatments. Surgeons become more aware of treatments that are affordable. The risk of endovascular treatment is lower than that of open surgery.
The longevity of endovascular treatments for iliac artery disease contributes to an increase in peripheral vascular surgeries. Favorable outpatient surgery reimbursement policies are also anticipated to fuel the market for peripheral vascular devices. An increase in outpatient cases due to a growth in end users, such as ambulatory surgery facilities in developing and poor nations, would further fuel the market for peripheral vascular devices.
“Stringent Regulations, Looming Threat of Product Recalls, Healthcare Cost, and Public Awareness“
The production and use of peripheral stent implants necessitate proper FDA guidelines, as improper storage causes chemical degradation, which reduces the stents' performance quality. Stents must go through rigorous clinical trials before they can be approved.
The use and production of novel vascular stents require approval from the Emergency Use Authorization (EUA), Food and Drug Administration (FDA), and the CE Mark. As a result, stringent regulations and lengthy approval processes tend to limit the growth of the peripheral stent implants market.
Food and Drug Administration (FDA) has recalled some technologically developed peripheral stent implants due to serious adverse health consequences like bleeding risk, and stokes. For example, in October 2015, Abbott Vascular was forced to recall its coronary catheters due to stemming risks.
Even though peripheral stent implants are more affordable than any surgical procedures, the patient must still be hospitalised, and the cost of the treatment is more than that of other pharmacological regimens such as lipid control medicines (ezetimibe, statin), and antiplatelet therapy (clopidogrel).
Future treatments for the asymptomatic PAD illness will prove to be a significant issue, thus developing nations in particular must raise public awareness of the disease and implement early detection programme.
Since early detection and treatment of the asymptomatic PAD condition are still important public health issues, thus; resource-limited nations must educate the public on these issues in the near future.
Why is the United States Market Booming?
“Market Penetration of Available Products and Increasing Prevalence of PAD”
The United States accounted for around 46.2% market share in the global market in 2022 because of increased prevalence of peripheral artery disease in the country. This is attributed to increased smoking, sedentary lifestyle, poor diet choices, cerebral and cardiovascular diseases, diabetes, and a large geriatric population. According to the Centers for Disease Control and Prevention, about 6.5 million people aged 40 and older in the United States will have PAD by 2022. Other health conditions and artery disorders can mimic PAD symptoms, and not all PAD is caused by atherosclerosis.
The easy availability of drug-eluting stents and better medical reimbursement policies in the United States are driving the growth of the peripheral stent implant market.
Will the Germany Be a Lucrative Market for Peripheral Stent Implants?
“Product Innovation and Manufacturing”
The German market held around 4.3% market share of the global market in 2022.
Apart from the prevalence of PAD and preference for non-invasive stent procedures, private and public sectors are investing in development of advanced stents in Germany. One of the key factors propelling the growth of the stents market is the rising prevalence of obesity among the people in the region. The market is growing because of an increase in percutaneous coronary intervention (PCI) operations and a high demand for minimally invasive surgeries (MIS), which have a number of benefits including small incision wounds, quick recovery, and shorter hospital stays.
The introduction of advanced DES, the development of bioresorbable scaffolds, and the rise in cardiovascular illnesses (CVDs), such as heart attack and stroke, all have an impact on the market.
How is China Emerging as a Prominent Market?
“Advanced Products, High Geriatric Population, and Increasing Product Exports”
China held a market share of about 4.9% of the global market in 2022.
The Chinese market is advanced and the key player in manufacturing of stent graft like stents, percutaneous transluminal angioplasty (PTA) balloon catheters, embolic protection devices for treatment of coronary arterial or PAD and suppling to the neighboring countries. For instance, India is the largest importer of China for stents, and importing stents such as LPRPS2736 GUREATER CoCR stent, LPRPS3012 NANO+TM polymer-free sirolimus eluting coronary stent system, and Firehawk rapamycin target eluting coronary stent system, etc.
Which Product is Driving Demand within the Global Market?
“Popularity of Bare Metal Stents Due to More Accurate Placement, and Higher Radial Stiffness”
Bare metal stents held about 75.9% share of the global market in 2022.
Bare metal stents are very popular, because there is no need for an incision and the procedure is generally carried out under local anesthetic. Other factor is rise in development of bioresorbable stents, and increase in number of cath labs, which are set to fuel the market growth in the forecast period.
The bare metal stents segment is divided into, balloon expandable stent products, balloon catheter, and self-expendable metallic stent. Balloon expandable stent is the most preferred one due to its higher radial stiffness and the more accurate placement.
Bare metal stent successfully reduced the incidence of restenosis and abrupt vessel closurewhen compared to balloon angioplasty, lowering the rate of target lesion revascularization (TLR).
Which Type of Artery is Largely in Focus within the Global Market?
“High Geriatric Population Propelling Iliac Artery Stents Demand”
Iliac artery stents held a market share of around 47.0% of the total market in 2022.
The primary factor driving the growth in the iliac artery stents demand is the global increase in atherosclerosis and cardiovascular disease incidences. Rapid technological advancement and widespread acceptance of stenting procedures among patients are also driving the growth in demand of iliac artery stents during the forecast period.
Rising geriatric population and increasing demand for minimally invasive surgery are also driving the iliac artery stents demand
Which End User is helping to expand the Global Market?
“Regulatory Overseeing for Medical Device Materials”
Hospitals hold a market share of around 58.4% of the global market in 2022.
The hospital segment was the largest contributor by end user in 2022 and is expected to maintain its lead during the forecast period. This is owed to the large number of patients opting to undergo angioplasty procedures in hospitals, an increase in the prevalence of coronary artery diseases, a government initiative to develop medical infrastructure, an increase in awareness about disease treatment and management, and an increase in sedentary lifestyle.
Key players are increasing sales and marketing growth investments with the development of global business network, which includes a large direct sales force, clinical specialists, distributors, and strategic partnerships to strengthen its marketing and sales capability.
In the international market, the key players collaborate with leading distributors to get rapid market penetration. Key players are also focusing on product developments with groundbreaking advancements, which are unique and highly efficient in use.
Some instances of developments in the market include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the peripheral stent implants market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2015 to 2022 |
|
Historical Data Available for |
2015 to 2022 |
|
Market Analysis |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product
Artery
End User
Region
To know more about delivery timeline for this report Contact Sales
The global market is valued at around US$ 3.6 Billion in 2022.
Sales of the market are set to witness growth at a CAGR of 6.7% and be valued at around US$ 7.2 Billion by 2033.
Demand for the global market increased at a 5.6% CAGR from 2015 to 2022.
The U.S., China, Germany, the U.K., and India account for most demand within the market, and were holding around 62.8% market share in 2022.
The U.S. accounts for around 46.2% share of the North American market in 2022.
The U.K. accounts for around 3.2% share of the global market in 2022.
The China market held a share of about 4.9% in the global peripheral stent implants market in 2022.
The peripheral stent implants market in India is holding 4.2% market share in the global market, in 2022.
Abbott Laboratories, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation, Cook Medical, Inc., Cardinal Health, Inc., iVascular SLU, Medtronic Plc., Terumo Corporation, and W. L. Gore & Associates Inc., are the key players of peripheral stent implants sector.
Bare metal stents held a market share of around 75.9% in 2022 global market.
